Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Holte

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Cytotherapy|August 13, 2002
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HDA K Blystad, E Torlakovic, H Holte, et al.
European Journal of Haematology. Supplementum|August 7, 2001
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patientsE Aurlien, H Holte, S Kvaløy, et al.
Acta Oncologica (Stockholm, Sweden)|July 27, 1999
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markersH Holte, Z Suo, E B Smeland, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's diseaseH Holte, O Mella, E Wist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2006
Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphomaU K H Haukvik, I Dieset, T Bjøro, et al.
Cancer Research|September 15, 1992
Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cellsT Stokke, H Holte, E B Smeland, et al.
Bone Marrow Transplantation|January 10, 2002
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cellsA K Blystad, H Holte, S Kvaløy, et al.
Bone Marrow Transplantation|April 1, 1996
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphomaK E Sletnes, H Holte, S Halvorsen, et al.
European Journal of Immunology|September 1, 1988
Cyclic AMP has the ability to influence multiple events during B cell stimulationH Holte, P Torjesen, H K Blomhoff, et al.
British Journal of Cancer|July 17, 1998
Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomasT Stokke, H Holte, L Smedshammer, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Cytotherapy|August 13, 2002
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HDA K Blystad, E Torlakovic, H Holte, et al.
European Journal of Haematology. Supplementum|August 7, 2001
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patientsE Aurlien, H Holte, S Kvaløy, et al.
Acta Oncologica (Stockholm, Sweden)|July 27, 1999
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markersH Holte, Z Suo, E B Smeland, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's diseaseH Holte, O Mella, E Wist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2006
Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphomaU K H Haukvik, I Dieset, T Bjøro, et al.
Cancer Research|September 15, 1992
Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cellsT Stokke, H Holte, E B Smeland, et al.
Bone Marrow Transplantation|January 10, 2002
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cellsA K Blystad, H Holte, S Kvaløy, et al.
Bone Marrow Transplantation|April 1, 1996
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphomaK E Sletnes, H Holte, S Halvorsen, et al.
European Journal of Immunology|September 1, 1988
Cyclic AMP has the ability to influence multiple events during B cell stimulationH Holte, P Torjesen, H K Blomhoff, et al.
British Journal of Cancer|July 17, 1998
Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomasT Stokke, H Holte, L Smedshammer, et al.
Pageof 10